Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing The Cigna Group’s dual-platform disclosures is challenging. One minute you’re untangling Express Scripts rebate economics, the next you’re scanning Medicare Advantage risk-score tables. These filings can exceed 300 pages, and critical details—like shifts in medical cost trends or specialty-drug margins—are buried deep.
Stock Titan solves that problem. Our AI-powered summaries flag the exact pages that explain opioid litigation reserves, translate actuarial footnotes into plain language, and deliver instant alerts the moment a Form 4 posts. Whether you need the latest 10-K footnote on Evernorth’s biosimilar strategy or a quick view of management’s stock grants, our platform keeps every SEC form in one place and refreshed in real time.
- The Cigna Group insider trading Form 4 transactions and The Cigna Group Form 4 insider transactions real-time
- The Cigna Group quarterly earnings report 10-Q filing and The Cigna Group earnings report filing analysis
- The Cigna Group annual report 10-K simplified, understanding The Cigna Group SEC documents with AI, and The Cigna Group executive stock transactions Form 4
- The Cigna Group proxy statement executive compensation
- The Cigna Group 8-K material events explained and The Cigna Group SEC filings explained simply
Use these filings to monitor pharmacy benefit margins, track segment revenue, or benchmark executive pay—all without wading through dense legal language. From real-time 8-K alerts on drug-pricing legislation to concise 10-Q trend charts, Stock Titan gives professionals the clarity they need to act decisively.
Q2 FY25 highlights (Preformed Line Products – PLPC): Net sales increased 22% YoY to $169.6 m; gross profit gained 25% to $55.4 m, lifting margin to 32.7%. Operating income jumped 52% to $17.1 m and net income attributable to shareholders rose 36% to $12.7 m, driving diluted EPS to $2.56 versus $1.89.
First-half FY25: Sales reached $318.1 m (+14%), operating income $30.3 m (+32%) and diluted EPS $4.89 (+28%). Cash climbed to $66.9 m while total debt expanded to $31.8 m, yielding a 7.9% debt-to-equity ratio. Operating cash flow slipped 4% to $32.6 m; capex surged to $19.4 m and the company closed a $5.3 m acquisition of Brazil-based JAP Telecom.
Segment trends: PLP-USA revenue +32%; The Americas +40% (acquisition boost); Asia-Pacific +20%; EMEA −5%. Energy products remained 70% of consolidated sales mix.
Balance-sheet & subsequent events: The PNC revolving facility was amended post-quarter to reduce capacity to $60 m; Polish subsidiary secured a PLN 100.3 m ($27.4 m) loan for a new plant. A U.S. pension plan termination in Q3 is expected to generate an $8.5-$9.5 m non-cash charge and require up to $3.5 m in funding. Effective tax rate rose to 27% from 16% due to fewer one-off benefits.
Management continues to invest despite tariff headwinds, aiming to leverage strong domestic demand and growing telecom exposure.
City Office REIT (CIO) swung to a heavy quarterly loss after writing down its soon-to-be-sold Phoenix Portfolio. Q2-25 rental revenue was flat at $42.3 million, but a $102.2 million impairment pushed operating results to a $96.6 million operating loss and a $105.3 million net loss (-$2.66 EPS) versus -$3.6 million (-$0.14 EPS) a year ago. Six-month net loss widened to $106.8 million. NOI was $26.0 million, up 4.7 % YoY, and operating cash flow remained positive at $25.4 million.
Balance-sheet capacity tightened: total assets fell to $1.33 billion from $1.46 billion at year-end, while debt was little changed at $647 million (4.5× annualised NOI). Cash and restricted cash totalled $34.5 million. Occupancy sat at 82.5 % with 3.6 % of leases expiring in 2H-25; several assets remain under covenant-triggered cash sweeps.
Strategic actions are reshaping the portfolio and capital structure. • 18 Jun 25: signed agreement to sell the 7-property Phoenix Portfolio for $296 million; assets and $16.8 million of liabilities reclassified as held for sale.
• 14 Jan 25: sold Superior Pointe for $12 million at book value.
• 23 Jul 25 (subsequent): entered a definitive merger agreement with MCME Carell to acquire all outstanding shares for $7.00 cash, subject to shareholder and customary approvals.
The board maintained the $0.10 quarterly common dividend (6.0 % annual yield at the $7.00 offer). Management continues to market non-core assets and manage refinancing risks ahead of the November 2025 unsecured facility maturity.
FAQ
What is the current stock price of Cigna Group (CI)?
What is the market cap of Cigna Group (CI)?
What does The Cigna Group do?
How does Cigna generate revenue?
What makes Cigna different from its competitors?
What is Evernorth Health Services?
What are Cigna Healthcare’s core offerings?
How does Cigna address healthcare affordability?
What is Cigna’s global reach?
How does Cigna contribute to community well-being?
What is Cigna’s approach to innovation?
What is Cigna’s commitment to transparency?
